Drug Information

Drug (ID: DG02039) and It's Reported Resistant Information

• Name: 10,12-Tricosadiynoic Acid
• Synonyms: 10,12-Tricosadiynoic acid|66990-30-5|tricosa-10,12-diynoic acid|10,12-Tricosadiynoicacid|DTXSID40337084|10,12- Tricosadiynoic acid|SCHEMBL302150|DTXCID30288172|CHEBI:190947|MFCD00041683|AKOS015839844|10,12-Tricosadiynoic Acid, >/=98%|PD127433|HY-135425|CS-0112754|T1200|10,12-Tricosadiynoic acid, >=98.0% (GC)|D92469|677-355-9
• Indication:
  In total 1 Indication(s)
  . .; .
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Chronic lymphocytic leukemia [ICD-11: 2A82]; [1]
• Formula: C23H38O2
• IsoSMILES: CCCCCCCCCCC#CC#CCCCCCCCCC(=O)O
• InChI: InChI=1S/C23H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23(24)25/h2-10,15-22H2,1H3,(H,24,25)
• InChIKey: DIEDVCMBPCRJFQ-UHFFFAOYSA-N
• PubChem CID: 538457

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Chronic lymphocytic leukemia [ICD-11: 2A82]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Acyl-CoA oxidase 1 (ACOX1) [1]

• Metabolic Type: Lipid metabolism
• Resistant Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HG3 cells; Blood; Homo sapiens (Human); CVCL_Y547
• In Vitro Model: MEC1 cells; Blood; Homo sapiens (Human); CVCL_1870
• In Vitro Model: OSU-CLL cells; Blood; Homo sapiens (Human); CVCL_Y382
• In Vitro Model: PGA1 cells; Blood; Homo sapiens (Human); CVCL_Y545
• In Vitro Model: Primary B-lymphocytes cells; Blood; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: qPCR, immunoblot and confocal microscopy approaches
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Accordingly, downmodulation of ACOX1 (a rate-limiting pFAO enzyme overexpressed in CLL cells) was enough to shift the CLL cells' metabolism from lipids to a carbon- and amino-acid-based phenotype. Complete blockade of ACOX1 resulted in lipid droplet accumulation and caspase-dependent death in CLL cells, including those from individuals with poor cytogenetic and clinical prognostic factors.

References

• Ref 1: ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia. Leukemia. 2024 Feb;38(2):302-317.